Skip to main content
Fig. 3 | World Journal of Surgical Oncology

Fig. 3

From: Clinicopathological significance of KAI1 expression and epithelial-mesenchymal transition in non-small cell lung cancer

Fig. 3

Disease-specific survival curves according to NSCLC cells co-expression of vimentin and E-cad. a In the total cohort of patients (n = 312), the median survival in the low E-cad/high vimentin group was 28.8 months, compared with 66.0 months in the high E-cad/low vimentin group and 43.3 months in the low E-cad/low vimentin group. b In all patients with N+ status (n = 159), the median survival in the low E-cad/high vimentin group was 48.4 months, compared with 69.1 months in the high E-cad/low vimentin group and 27.4 months in the low E-cad/low vimentin

Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us